Last reviewed · How we verify
NCT06585397
ICF-Based Evaluation of the Upper Extremity in Children With Quadriparetic Cerebral Palsy
trial testing Grup 1 in Upper Extremity Spasticity in 20 participants. Completed in 1 September 2024.
1 September 2024
Quick facts
| Lead sponsor | Acıbadem Atunizade Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 August 2024 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Grup 1
Conditions studied
- Upper Extremity Spasticity — all drugs for Upper Extremity Spasticity →
- Quadriplegic Cerebral Palsy — all drugs for Quadriplegic Cerebral Palsy →
Sponsor
Acıbadem Atunizade Hospital
Who can join
Under 17, any sex, with Upper Extremity Spasticity or Quadriplegic Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cerebral palsy (CP) is a neurodevelopmental disorder characterized by abnormalities in muscle tone, movement, and motor skills resulting from permanent, non-progressive damage to the developing brain before, during, or after birth. The worldwide prevalence of CP is 2-3 per 1000 live births. Spastic CP accounts for approximately 85% of all CP cases. Among the types of spastic CP, quadriparetic CP (QCP) is the most severe and accounts for 20% of spastic CP cases. Individuals diagnosed with quadriparetic cerebral palsy (QCP) are restricted from participating in daily life activities due to inadequate upper extremity function (spasticity, muscle weakness, inability to perform isolated movements, and limitation of supination movements). In order to correctly evaluate children diagnosed with QCP and determine treatment priorities, it is very important to evaluate them based on the International Classification of Functioning, Disability, and Health (ICF). In the literature, there is no study that evaluates the upper extremity of individuals with isolated QCP based on ICF. The aim of this study is to examine the upper extremity functions of individuals with isolated QCP diagnosis within the framework of ICF.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06585397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Acıbadem Atunizade Hospital trials
Trials by the same sponsor.
- NCT07407075 — MUSCLE STRENGTH IMBALANCE AND KINESIOPHOBIA IN MENISCUS PATIENTS · completed
- NCT06599281 — The Importance of Physiotherapy After Separation Surgery in Pygopagus Conjoined Twins · NA · not yet recruiting
- NCT06617507 — The Effect of Selective Dorsal Rhizotomy Surgery on Walking in Children With Ambulatory Cerebral Palsy in Turkey · completed
- NCT06610370 — Predicting Postoperative Ambulation Following Selective Dorsal Rhizotomy Based on Preoperative Gross Motor Function Scor · completed
- NCT06610357 — Evaluation of Long-Term Effects of Selective Dorsal Rhizotomy Surgery on Function and Mobility in Children With Cerebral · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06585397 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Acıbadem Atunizade Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing